In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

1. (original) A compound of formula (I)



or a salt, ester or prodrug thereof;

where:

X is O or NR^6;

$\mathbf{R^6}$ is hydrogen or C_{1-4}alkyl;

$\mathbf{R^1}$ is hydrogen, halo, or $-X^1R^{11}$;

$\mathbf{X^1}$ is a direct bond, $-CH_2=CH_2-$, -O-, -NH-, $-N(C_{1-6}alkyl)-$, -C(O), -C(O)O, -OC(O)-, -NHC(O)-, $-N(C_{1-6}alkyl)C(O)-$, -C(O)NH or $-C(O)N(C_{1-6}alkyl)-$;

$\mathbf{R^{11}}$ is hydrogen, or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, heterocyclyl, heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, $-NR^9R^{10}$, $-C(O)R^9$, $-C(O)NR^9R^{10}$ and $-C(O)OR^9$;

$\mathbf{R^2}$ is hydrogen, halo, nitro, cyano or $-X^2R^{12}$;

$\mathbf{X^2}$ is a direct bond, -O-, -NH-, $-N(C_{1-6}alkyl)-$, -OC(O)- or -C(O)O-;

$\mathbf{R^{12}}$ is hydrogen, or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, aryl, arylC_{1-4}alkyl, arylC_{2-4}alkenyl, arylC_{2-4}alkynyl, heterocyclyl, heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl, which group is optionally substituted by 1, 2 or 3 substituents independently selected from, halo, hydroxy, C_{1-4}alkyl, C_{1-4}alkoxy, $-NR^{15}R^{16}$, $-NHC(O)NR^{15}R^{16}$, $-C(O)R^{15}$ and $-C(O)OR^{15}$;

$\mathbf{R^3}$ is hydrogen, halo or $-X^3R^{13}$;

$\mathbf{X^3}$ is a direct bond, $-CH_2=CH_2-$, -O-, -NH-, $-N(C_{1-6}alkyl)-$, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, $-N(C_{1-6}alkyl)C(O)-$, -C(O)NH- or $-C(O)N(C_{1-6}alkyl)-$;

$\mathbf{R^{13}}$ is hydrogen, or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, aryl, arylC_{1-4}alkyl, arylC_{2-4}alkenyl, arylC_{2-4}alkynyl, heterocyclyl,

heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from $-NR^7R^8$, $-C(O)NR^7R^8$, halo, hydroxy, C_{1-4}alkyl, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, hydroxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl;

R^7 and **R^8** are independently selected from hydrogen, heterocyclyl, heterocyclylC_{1-4}alkyl, C_{1-4}alkylheterocyclylC_{1-4}alkyl, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-4}alkoxyC_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{3-6}cycloalkyl, hydroxyC_{1-4}alkylC_{3-6}cycloalkyl, hydroxyC_{1-4}alkylC_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{3-6}cycloalkylC_{1-4}alkyl, C_{1-4}alkoxyC_{3-6}cycloalkyl, C_{1-4}alkoxyC_{3-6}cycloalkylC_{1-4}alkyl, haloC_{1-6}alkyl, haloC_{3-6}cycloalkyl, haloC_{3-6}cycloalkylC_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, cyanoC_{1-4}alkyl, aminoC_{1-6}alkyl, C_{1-4}alkylaminoC_{1-6}alkyl, bis(C_{1-4}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl;

or **R^7** and **R^8** together with the nitrogen to which they are attached form a heterocyclic ring which ring is moncyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO_2, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C_{1-4}alkyl, hydroxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkoxy, hydroxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl, and where a ring $-CH_2-$ is optionally replaced with $-C(O)-$;

R^4 is selected from hydrogen, halo or $-X^4R^{14}$;

X^4 is a direct bond, -O-, -NH- or $-N(C_{1-6}alkyl)-$;

R^{14} is selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl;

R^5 is aryl or heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, cyano, nitro, amino, C_{1-4}alkylamino, bis(C_{1-4}alkyl)amino, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, $-C(O)NHR^{17}$, $-NHC(O)R^{18}$, $-SR^{17}$, $-S(O)R^{17}$ and $-S(O)OR^{17}$;

R^9, R^{10}, R^{15} and **R^{16}** are independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl, aminoC_{1-6}alkyl, C_{1-4}alkylaminoC_{1-6}alkyl and bis(C_{1-4}alkyl)aminoC_{1-6}alkyl;

or **R^9** and **R^{10}** together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO_2, and which ring is

optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C_{1-4}alkyl, hydroxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkoxy, hydroxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl, and where a ring $-CH_2-$ is optionally replaced with -C(O)-;
$\mathbf{R^{17}}$ and $\mathbf{R^{18}}$ are independently selected from hydrogen, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl and C_{2-4}alkynyl.

2. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein X is NH.

3. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein R^4 is hydrogen.

4. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein R^5 is aryl optionally substituted by 1 or 2 halo.

5. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein R^1 is hydrogen or $-OR^{11}$ and R^{11} is hydrogen, heterocyclyl selected from piperidinyl or pyrrolidinyl or C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by hydroxy, C_{1-4}alkoxy, amino, C_{1-4}alkylamino or bis(C_{1-4}alkyl)amino.

6. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein R^2 is hydrogen or $-OR^{12}$ and R^{12} is hydrogen, C_{1-4}alkyl, heterocyclyl or heterocyclylC_{1-4}alkyl.

7. (original) A compound according to claim 1 or a salt, ester or prodrug thereof wherein R^3 is $-X^3R^{13}$, X^3 is $-CH_2=CH_2-$, -O- or -NH-, and R^{13} is C_{1-6}alkyl substituted by $-NR^7R^8$, heterocyclyl or halo.

8. (original) A compound according to claim 7 or a salt, ester or prodrug thereof wherein R^7 and R^8 are independently selected from hydrogen, heterocyclyl, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, hydroxyC_{1-4}alkylC_{3-6}cycloalkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, haloC_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, cyanoC_{1-4}alkyl and bis(C_{1-4}alkyl)aminoC_{1-6}alkyl; or R^7 and R^8 together with the nitrogen to which they are attached form a heterocyclic ring which ring comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally

NH or O and which ring is optionally substituted on carbon or nitrogen by a group selected from C_{1-4}alkyl, hydroxy, hydroxyC_{1-4}alkyl and hydroxyC_{1-4}alkoxyC_{1-4}alkyl, and where a ring $-CH_2-$ is optionally replaced with –C(O)-.

9. (original) A compound of formula (IA)



or a salt or ester thereof

where X, X^1, X^2, X^3, R^4 and R^5 are as defined in relation to formula (I) in claim 1 and

$R^{1'}$ is hydrogen, halo, or $-X^1R^{11'}$;

$R^{11'}$ is hydrogen, phosphonooxy or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, heterocyclyl, heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, phosphonooxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkyl, $-NR^{9'}R^{10'}$, $-C(O)R^{9'}$, $-C(O)NR^{9'}R^{10'}$ and $-C(O)OR^{9'}$;

$R^{2'}$ is hydrogen, halo, nitro, cyano or $-X^2R^{12'}$;

$R^{12'}$ is hydrogen, phosphonooxy or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, aryl, arylC_{1-4}alkyl, arylC_{2-4}alkenyl, arylC_{2-4}alkynyl, heterocyclyl, heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl, which group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, phosphonooxy, C_{1-4}alkyl, C_{1-4}alkoxy, $-NR^{15'}R^{16'}$, $-NHC(O)NR^{15'}R^{16'}$, $-C(O)R^{15'}$ and $-C(O)OR^{15'}$;

$R^{3'}$ is hydrogen, halo or $-X^3R^{13'}$;

$R^{13'}$ is hydrogen, phosphonooxy or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, aryl, arylC_{1-4}alkyl, arylC_{2-4}alkenyl, arylC_{2-4}alkynyl, heterocyclyl, heterocyclylC_{1-4}alkyl, heterocyclylC_{2-4}alkenyl and heterocyclylC_{2-4}alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from $-NR^{7'}R^{8'}$, $-C(O)NR^{7'}R^{8'}$, halo, hydroxy, phosphonooxy, C_{1-4}alkyl, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, phosponooxyC_{1-4}alkyl, hydroxyC_{1-4}alkylcarbonyl, phosphonooxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl;

$R^{7'}$ and $R^{8'}$ are independently selected from hydrogen, heterocyclyl, heterocyclylC_{1-4}alkyl, C_{1-4}alkylheterocyclylC_{1-4}alkyl, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, phosphonooxyC_{1-6}alkyl, C_{1-4}alkoxyC_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{3-6}cycloalkyl, phosphonooxyC_{3-6}cycloalkyl, hydroxyC_{1-4}alkylC_{3-6}cycloalkyl, phosphonooxyC_{1-4}alkylC_{3-6}cycloalkyl, hydroxyC_{3-6}cycloalkylC_{1-4}alkyl, phosphonooxyC_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{1-4}alkylC_{3-6}cycloalkylC_{1-4}alkyl, phosphonooxyC_{1-4}alkylC_{3-6}cycloalkylC_{1-4}alkyl, C_{1-4}alkoxyC_{3-6}cycloalkyl, C_{1-4}alkoxyC_{3-6}cycloalkylC_{1-4}alkyl, haloC_{1-6}alkyl, haloC_{3-6}cycloalkyl, haloC_{3-6}cycloalkylC_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, cyanoC_{1-4}alkyl, aminoC_{1-6}alkyl, C_{1-4}alkylaminoC_{1-6}alkyl, bis(C_{1-4}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkylcarbonyl, phosphonooxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl;

or $R^{7'}$ and $R^{8'}$ together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO_2, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C_{1-4}alkyl, hydroxy, phosphonooxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkoxy, hydroxyC_{1-4}alkylcarbonyl, phosphonooxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl, and where a ring $-CH_2-$ is optionally replaced with -C(O)-;

$R^{9'}$, $R^{10'}$, $R^{15'}$ and $R^{16'}$ are independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, hydroxyC_{1-6}alkyl, phosphonooxyC_{1-6}alkyl, haloC_{1-6}alkyl, aminoC_{1-6}alkyl, C_{1-4}alkylaminoC_{1-6}alkyl and bis(C_{1-4}alkyl)aminoC_{1-6}alkyl;

or $R^{9'}$ and $R^{10'}$ together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO_2, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C_{1-4}alkyl, hydroxy, phosphonooxy, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxyC_{1-4}alkoxyC_{1-4}alkyl, phosphonooxyC_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkoxy, hydroxyC_{1-4}alkylcarbonyl, phosphonooxyC_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl, aminoC_{1-4}alkylcarbonyl, C_{1-4}alkylaminoC_{1-4}alkylcarbonyl and bis(C_{1-4}alkyl)aminoC_{1-4}alkylcarbonyl, and where a ring $-CH_2-$ is optionally replaced with -C(O)-;

provided that a compound of formula (IA) contains at least one phosphonooxy group.

10. (original) A compound according to claim 9 or a salt or ester thereof wherein the compound or salt or ester thereof contains only one phosphonooxy group.

11. (original) A compound according to claim 9 or a salt or ester thereof wherein X is NH.

12. (original) A compound according to claim 9 or a salt or ester thereof wherein R^4 is hydrogen.

13. (original) A compound according to claim 9 or a salt or ester thereof wherein R^5 is aryl optionally substituted by 1 or 2 halo.

14. (currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof~~, or a compound of formula (IA) as defined in claim 9 or a pharmaceutically acceptable salt or ester thereof~~ in association with a pharmaceutically acceptable diluent or carrier.

15-17. (cancelled)

18. (currently amended) A method of treating a human suffering from a hyperproliferative disease such as cancer comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof ~~or a compound of formula (IA) as claimed in claim 9 or a pharmaceutically acceptable salt or ester thereof~~.

19. (original) A process for the preparation of a compound of formula (I) as defined in claim 1 or a salt, ester or prodrug thereof, which process comprises reacting a compound of formula (II) wherein R^1, R^2, R^3 and R^4 are as defined in claim 1



(II)

where L is a suitable leaving group with a compound of formula (III) wherein R^5 and X are as defined in claim 1



(III)

in the presence of hydrochloric acid in dioxane under an inert atmosphere,
and thereafter if necessary:
i) converting a compound of the formula (I) into another compound of the formula (I); and/or
ii) removing any protecting groups; and/or
iii) forming a salt, ester or prodrug thereof.

20. (original) A process for the preparation of a compound of formula (IA) as defined in claim 9 or a salt or ester thereof, which process comprises phosphorylation of a suitable compound of formula (I) followed by deprotection of the phosphate group.

21. (new) A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 9 or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutically acceptable diluent or carrier.

22. (new) A method of treating a human suffering from a hyperproliferative disease such as cancer comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound of formula (IA) as claimed in claim 9 or a pharmaceutically acceptable salt or ester thereof.

23. (new) A compound selected from any one of:
2-(4-{[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)-*N*-(3-fluorophenyl)acetamide;
2-(4-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)-*N*-(3-fluorophenyl)acetamide;
(4-{[7-(3-chloropropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)-*N*-(2,3-difluorophenyl)acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(propyl)amino]propoxy}-6-methoxyquinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(propyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-(4-{[7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(3-fluorophenyl)-2-(4-{[7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(3-fluorophenyl)-2-(4-{[7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
2-[4-({7-[3-(cyclopropylamino)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]-*N*-(3-fluorophenyl)acetamide;
2-{4-[(7-{3-[[2-(dimethylamino)ethyl](methyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(3-fluorophenyl)acetamide;
N-(3-fluorophenyl)-2-[4-({7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-[4-({7-[3-(4-hydroxypiperidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;
2-{4-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(3-fluorophenyl)acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-(4-{[7-(3-piperazin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(isopropyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
2-{4-[(7-{3-[cyclopropyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(3-fluorophenyl)acetamide;
N-(2,3-difluorophenyl)-2-(4-{[7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(2,3-difluorophenyl)-2-(4-{[7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(2,3-difluorophenyl)-2-(4-{[7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
2-[4-({7-[3-(cyclopropylamino)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]-*N*-(2,3-difluorophenyl)acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[[2-(dimethylamino)ethyl](methyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-[4-({7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-[4-({7-[3-(4-hydroxypiperidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-(4-{[7-(3-piperazin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;
N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(isopropyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide; and
2-{4-[(7-{3-[cyclopropyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(2,3-difluorophenyl)acetamide;

or a salt, ester or prodrug thereof.